Artivion Inc (AORT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Artivion Inc stock $3.48, price $20.21, that is 82.8% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $10.01 – $47.63 · fair‑value band $2.44 – $4.52 · the $20.21 price screens above the $3.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Artivion in your weekly email
Every Wednesday you see whether Artivion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Show moreShow less
The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries.
In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated.
It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.
Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Stock analysis
Artivion Inc (AORT) currently trades at $20.21, while our model-based Fair Value estimate is $3.48, 83% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $3.94 per share, and 0 of the 14 models we run sit above the $20.21 price.
Bear case: the Asset-Based group reads lowest at $0.5200, and 14 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: $2.44 (bear) to $4.52 (bull), the price of $20.21 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Artivion Inc reported revenue of $441M in FY2025 versus $299M in FY2021, a compound +10.2%/yr. Reported net income was $9.8M in FY2025.
Key figures
Market cap $1.2B Small · P/S ratio 2.56 · EPS (TTM) $−0.0700 · Net margin 2.2% · Return on equity −4.0% · Return on assets (EBIT) 2.1% (5-year average) · Operating margin 2.4% · Revenue (TTM) $482M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 58% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −83%, AORT screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.5200 to $9.47). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear$2.44Fair Value $3.48Bull$4.52
Price $20.21 · Downside -82.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 4 officers or directors sold shares worth $3.5M and none bought.
SaleAndrew M GreenSVP, Regulatory and Quality4× since Jun 11, 2026: 64,100 shares, avg. $22.33$1.4MSep 10, 2026
SaleJames P MackinPresident & CEO8× since Nov 10, 2025: 251,328 shares, avg. $38.69$9.7MAug 19, 2026
SaleLance A BerryEVP, COO, CFO & Treasurer4× since Feb 23, 2026: 21,675 shares, avg. $37.06$803,205Aug 14, 2026
SaleJean F HollowaySVP, General Counsel8× since Nov 10, 2025: 59,535 shares, avg. $42.63$2.5MAug 12, 2026
SaleJohn E DavisChief Commercial Officer7× since Nov 10, 2025: 40,928 shares, avg. $42.66$1.7MMar 3, 2026
SaleMarshall S. StantonSVP, Clinical & MD Affair7× since Nov 10, 2025: 77,555 shares, avg. $44.19$3.4MMar 3, 2026
SaleAmy HortonVP, Chief Accounting Officer7× since Nov 10, 2025: 19,946 shares, avg. $43.62$870,080Mar 3, 2026
SaleElizabeth A HoffDirector4,200 shares at $45.10$189,420Nov 18, 2025
Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic). Over 10 years: +11.7% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
≈ +59.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +59.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 35.4% / −2.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 6%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.043 per share, median 0.11 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside−82.8% · Bottom 25%
Profitability
Return on assets1.1% · Below median
Net margin (12 months)−3.7% · Below median
Operating margin (12 months)2.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)9.2% · Above median
Balance sheet
Debt / equity0.48× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B2.76× · Pricier than median
P/S (12 months)2.56× · Cheaper than median
EV/EBITDA36.1× · Priciest 25%
PEG643.75× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)46· sector 36
PAST (return on equity)0· sector 17
HEALTH (low debt)76· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Artivion Inc Fair Value". https://www.fairvalue-calculator.com/stock/AORT
Frequently asked questions
Is Artivion Inc (AORT) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $3.48 versus a price of $20.21, about 83% lower (overvalued).
What is the fair value of AORT?
Our model-based fair value for Artivion Inc is $3.48 (as of Nov 6, 2026), built from audited fundamentals. The current price: $20.21.
What is the quality score of AORT?
Artivion Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Artivion Inc (AORT)?
Our model-based price target is the fair value of $3.48 (as of Nov 6, 2026) from 14 valuation models. Cautious scenario $2.44, optimistic scenario $4.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Artivion Inc stock forecast for 2026?
Our models put fair value at $3.48, about 83% lower versus a price of $20.21 (overvalued). Cautious scenario $2.44, optimistic scenario $4.52. The calculation is refreshed regularly with new filings.
What is the revenue of Artivion Inc (AORT)?
Artivion Inc reported trailing-twelve-month revenue of about $482M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Artivion Inc (AORT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Artivion Inc it is $3.48 per share (as of Nov 6, 2026), against a price of $20.21. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Artivion Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, AORT trades above its calculated fair value: price $20.21, fair value $3.48, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AORT?
No. The price is what the market pays today ($20.21); the fair value is what the company's own numbers justify ($3.48). For Artivion Inc the two are $16.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Artivion Inc worth?
The market values Artivion Inc at about $1.2B (market capitalisation, as of Nov 6, 2026). Per share that is $20.21; our models calculate a fair value of $3.48 per share.
What do the bullish and bearish scenarios say about AORT?
Our models span a range for Artivion Inc: cautious scenario $2.44, base $3.48, optimistic $4.52 per share (as of Nov 6, 2026, price $20.21). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Artivion Inc (AORT)?
Balance-sheet figures for Artivion Inc (as of Nov 6, 2026): return on equity −4.0%, debt of 0.48 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is AORT from its 52-week high?
Artivion Inc trades at $20.21, about 58% below its 52-week high of $47.63 and 1% above the low of $20.10 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.48 is for.
Which stocks are comparable to Artivion Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Artivion Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $20.21, calculated fair value $3.48 (−83%), Quality Score 41/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AORT calculated?
We run Artivion Inc through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $3.48 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Artivion Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Artivion Inc (AORT)?
The closing price on Nov 6, 2026 was $20.21. Our model-based fair value is $3.48, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Artivion Inc right now?
The price sits above even our optimistic bull case ($4.52). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.44 to $4.52) leaves room in how you read the outcome.
Key figures of Artivion Inc
How large is the market capitalisation of Artivion Inc (AORT)?
The market capitalisation of Artivion Inc is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Artivion Inc (AORT)?
The price-to-sales ratio of Artivion Inc is 2.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Artivion Inc (AORT)?
Earnings per share at Artivion Inc are $−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Artivion Inc (AORT)?
The net margin of Artivion Inc is 2.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Artivion Inc (AORT)?
The return on equity (ROE) of Artivion Inc is −4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Artivion Inc (AORT)?
On an EBIT basis the return on assets of Artivion Inc is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Artivion Inc (AORT)?
The operating margin of Artivion Inc is 2.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Artivion Inc (AORT)?
Revenue at Artivion Inc is growing +9.2% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Artivion Inc (AORT) generate?
The free cash flow of Artivion Inc is −$911K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Artivion Inc (AORT) carry?
The net debt of Artivion Inc is $227M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Artivion Inc in the live analysis
One click puts Artivion Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
